Tetrahydrobiopterin
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00208780 | Dec 2004 → Dec 2005 | hypertensive disorder | Emory University | Completed | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT05114226 | Mar 2022 → Nov 2023 | radiodermatitis | West China Second University Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT04800692 | Jun 2021 → Jul 2027 expected | intermittent vascular claudication, peripheral arterial disease | Louis Messina | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04014712 | Apr 2021 → Aug 2022 | chronic obstructive pulmonary disease, tetrahydrobiopterin metabolic process disease | University of Massachusetts, Amherst | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00244218 | Apr 2005 → Mar 2009 | phenylketonuria | The University of Texas Medical Branch, Galveston | Terminated | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05138887 | Mar 2022 → Oct 2023 | enteritis | West China Second University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01439555 | Nov 2011 → Nov 2017 | Alzheimer disease | University of Massachusetts, Worcester | Completed | No outcome recorded |
| Phase 2 | NCT01356966 | May 2011 → May 2014 | chronic kidney disease | Emory University | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00432822 | — | disorder of phenylalanine metabolism | Orphanetics Pharma Entwicklungs GmbH | Terminated | No outcome recorded |
| Phase not applicable1 trial · 1 met primary | ||||||
| — | NCT01398943 | Sep 2010 → Jun 2015 | chronic obstructive pulmonary disease | Augusta University | Completed | Met primary |
Press releases naming this drug 8 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetrahydrobiopterin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01439555 ↗ |
| Known as | 5,6,7,8-Tetrahydrobiopterin | “5,6,7,8-Tetrahydrobiopterin (BH4) is an essential cofactor for nitric oxide synthases (NOS) and aromatic amino acid hydroxylases, and its biosynthesis involves de novo...” PMID 34513700 ↗ Aug 20211“5,6,7,8-Tetrahydrobiopterin (BH4) is an essential cofactor for all nitric oxide synthases.” PMID 28596000 ↗ Jun 2017 |
| Known as | BH4 | “The purpose of this study is to assess the efficacy of supplementation with tetrahydrobiopterin (BH4) for improving vascular and muscle function in patients with COPD and...” NCT04014712 ↗8“Tetrahydrobiopterin (BH4) is an essential cofactor for nitric oxide (NO) synthesis and a regulator of endothelial function.” PMID 29705218 ↗ Apr 2018 “Tetrahydrobiopterin (BH4), also known as Sapropterin, is an important cofactor of the nitric oxide synthase (NOS) enzyme.” NCT05138887 ↗ “Tetrahydrobiopterin (BH4), also known as Sapropterin, is an important cofactor of the nitric oxide synthase (NOS) enzyme.” NCT05114226 ↗ “Tetrahydrobiopterin (BH(4)) is a cofactor for the nitric oxide (NO) synthase enzymes” PMID 18322548 ↗ Mar 2008 “Tetrahydrobiopterin (BH4) is a cofactor for the nitric oxide (NO) synthase enzymes” NCT00208780 ↗ “Tetrahydrobiopterin (BH4), an essential cofactor for nitric oxide synthase” PMID 26962106 ↗ Mar 2016 “tetrahydrobiopterin (BH4)” NCT00432822 ↗ “BH4” NCT00244218 ↗ |
| Known as | Sapropterin | “Tetrahydrobiopterin (BH4), also known as Sapropterin, is an important cofactor of the nitric oxide synthase (NOS) enzyme.” NCT05138887 ↗1“Tetrahydrobiopterin (BH4), also known as Sapropterin, is an important cofactor of the nitric oxide synthase (NOS) enzyme.” NCT05114226 ↗ |
| Route | Oral | “was administered orally” NCT00208780 ↗ |